Skip to content
Search

Latest Stories

Study warns of rising uterine cancer rates, with Black women hardest hit

The study found that Black women already experience double the mortality rate

Black women cancer risk

Serious public health challenges in the decades ahead

iStock

Key points

  • Uterine cancer cases and deaths are projected to rise significantly in the US by 2050.
  • Black women are expected to experience the highest increase in incidence-based mortality.
  • A new model predicts incidence rising to 86.9 cases per 100,000 for Black women and 74.2 for White women.
  • Researchers stress the urgent need for improved prevention and early detection strategies.

Sharp increase in uterine cancer predicted over next three decades

Uterine cancer, currently the fourth most commonly diagnosed cancer among women in the United States, is projected to see a substantial rise in both cases and deaths by 2050, particularly among Black women. A new study led by researchers at Columbia University warns of worsening racial disparities in outcomes if preventative measures are not introduced.

This year alone, around 69,120 new cases of uterine cancer and nearly 14,000 deaths are expected in the United States. However, projections by the Columbia University research team, published in Cancer Epidemiology, Biomarkers & Prevention, indicate a significant increase in both incidence and mortality over the next 30 years.


Black women to face disproportionate increase in mortality

The study found that Black women already experience double the mortality rate from uterine cancer compared to women from other racial and ethnic backgrounds. Using a predictive model, researchers estimated that this gap will widen dramatically by 2050.

The incidence-based mortality rate among Black women is expected to rise from 14.1 per 100,000 in 2018 to 27.9 per 100,000 by 2050. In contrast, for White women, the rate will increase from 6.1 per 100,000 to 11.2 per 100,000 in the same period.

The incidence rate is also projected to rise to 86.9 cases per 100,000 in Black women and 74.2 cases per 100,000 in White women by 2050, compared to 56.8 and 57.7, respectively, in 2018.

About the study model

The projections were developed using the Columbia University Uterine Cancer Model (CU-UTMO), a state-transition microsimulation tool designed as part of the National Cancer Institute’s Cancer Intervention and Surveillance Modeling Network (CISNET).

The model simulates the disease trajectory based on age (18–84), race (Black and White), tumour type (endometrioid or nonendometrioid), stage at diagnosis, and birth cohort from 1910 onwards. It was validated using 2018 data and showed a strong fit to actual incidence and mortality statistics.

Lead author Dr Jason D. Wright, the Sol Goldman Professor of Gynaecologic Oncology at Columbia University, explained:

“There are likely a number of factors that are associated with the increased burden of uterine cancer in Black women. They more commonly have aggressive types of uterine cancer, face delayed diagnosis resulting in later-stage disease at diagnosis, and there are often delays in their treatment.”

More aggressive tumour types in Black women

The model also highlighted that while endometrioid tumours, a less aggressive form, are projected to increase in both Black and White women, the rate of nonendometrioid tumours, which have a poorer prognosis, will rise considerably in Black women alone.

These trends point to an urgent need for improved public health interventions aimed at early diagnosis and treatment, as well as research into tailored approaches for high-risk groups.

Potential for prevention and screening

In a stress test of the model, researchers incorporated hypothetical screening methods capable of detecting uterine cancer and precancerous changes before clinical diagnosis. The analysis found that such interventions could lead to significant reductions in cancer incidence, lasting up to 15 years in White women and 16 years in Black women, if introduced at the age of 55.

Dr Wright commented on the implications of the test:

“The stress testing suggests that if there was an effective screening test, we may be able to substantially reduce the burden of disease. While there is presently no screening or prevention that is routinely used for uterine cancer, we are currently examining the potential impact of integrating screening into practice.”

Call for action

With cases and deaths from uterine cancer projected to climb, the researchers conclude that immediate steps must be taken to develop and implement primary and secondary prevention strategies. Without intervention, the burden of uterine cancer, particularly among Black women, is expected to grow significantly, posing serious public health challenges in the decades ahead.

More For You

Serena Williams

Williams explained that her weight challenges began after the birth of her first daughter

Getty Images

Serena Williams says GLP-1 made her feel light physically and mentally after 31lb loss

Highlights:

  • Serena Williams reveals she has lost more than 31lbs using a GLP-1 medication
  • The tennis legend says the treatment enhanced her existing healthy lifestyle
  • She stresses that weight loss should not change self-image or self-confidence

Serena Williams has revealed she has lost more than 31lbs after turning to a weight-loss medication, saying the treatment has transformed both her body and her mindset.

The 23-time Grand Slam champion, 43, told PEOPLE that using a GLP-1 medication — a type of injection that works by regulating appetite — has helped enhance the healthy lifestyle she already maintained through diet and exercise.

Keep ReadingShow less
Monica Seles

Seles first began noticing symptoms around five years ago

Getty Images

Tennis champion Monica Seles reveals living with myasthenia gravis

Highlights:

  • Nine-time Grand Slam winner Monica Seles diagnosed with myasthenia gravis three years ago
  • The 51-year-old revealed her condition ahead of this month’s US Open to raise awareness
  • Disease causes muscle weakness and has no known cure

Former world number one Monica Seles has revealed she was diagnosed with myasthenia gravis, a rare neuromuscular autoimmune disease, three years ago. The 51-year-old, who won nine Grand Slam singles titles, went public ahead of the US Open to raise awareness of the condition, which causes muscle weakness and can affect multiple parts of the body.

Symptoms and diagnosis

Seles first began noticing symptoms around five years ago when she experienced double vision and struggled with coordination. “I would be playing [tennis] with some kids or family members, and I would miss a ball. I was like, ‘Yeah, I see two balls,’” she told the Associated Press. These symptoms eventually led to her diagnosis, which took time for her to come to terms with.

Keep ReadingShow less
faulty knee implant NHS recall

Hundreds of patients required corrective surgery

iStock

Faulty knee implant recalled after being used in over 10,000 NHS surgeries

Highlights:

  • NexGen knee implant linked to high failure rates was used in over 10,000 UK operations.
  • Concerns flagged as early as 2014; withdrawn from UK market in 2022.
  • Hundreds of patients required corrective surgery, with costs running into millions.
  • Manufacturer Zimmer Biomet says patient safety is its “top priority” but will not cover revision costs up front.

Implant used despite early warnings

A knee replacement implant used in thousands of NHS operations was known to have a concerning failure rate eight years before it was withdrawn, a BBC File on 4 Investigates report has found.

The NexGen implant, made by US manufacturer Zimmer Biomet, was fitted in more than 10,000 patients between 2012 and 2022. Concerns were first raised by the National Joint Registry (NJR) in 2014, though insufficient data at the time made it difficult to draw firm conclusions.

Keep ReadingShow less
health

A 34-year-old woman developed 43 aggressive skin cancer lesions triggered by HPV

iStock

Oral sex linked to skin cancer risk through stealth HPV infections, scientists warn

Highlights:

  • HPV, a common STI, is now potentially linked to a deadly form of skin cancer
  • A 34-year-old woman developed 43 aggressive skin cancer lesions triggered by HPV
  • Researchers say this discovery could shift the approach to diagnosing and treating some skin cancers
  • Protection measures include vaccination, safe sex practices, and regular screening


Human papillomavirus (HPV), one of the most widespread sexually transmitted infections in the UK, is already associated with several serious cancers — cervical, throat, penile, anal, and head and neck cancers among them. Now, researchers in the US have raised concerns that it may also contribute to certain forms of skin cancer, especially in people with weakened immune systems.

Scientists from the National Institutes of Health (NIH) found signs of beta-HPV triggering squamous cell carcinoma in a young woman who had no major history of sun damage or other typical causes.

Keep ReadingShow less
CardioPrecision

The approach aims to reduce pain, shorten hospital stays, and improve patient outcomes

MediaZoo

CardioPrecision performs world-first robot-assisted aortic valve replacement via neck incision

Highlights:

  • Glasgow-based CardioPrecision completes first clinical cases of robotic aortic valve replacement (AVR) through a small neck incision.
  • The procedure was carried out at Cleveland Clinic in the United States.
  • It uses the company’s CoreVista® Robot Enabling Platform to perform minimally invasive surgery.
  • The approach aims to reduce pain, shorten hospital stays, and improve patient outcomes.
  • Early results presented at major international conferences show clinical promise.


Glasgow medtech firm CardioPrecision has successfully performed the world’s first clinical cases of robot-assisted aortic valve replacement (AVR) using a small transcervical incision. This breakthrough could significantly reduce the need for traditional open-heart surgery.

The pioneering operations were carried out at the Cleveland Clinic in the United States, a centre globally recognised for its cardiovascular care. The procedures used CardioPrecision’s proprietary CoreVista® Robot Enabling Platform, offering a new route for accessing the heart valve via the neck rather than the chest.

Keep ReadingShow less